AdipoPharma Targets Root Cause Of Diabetes With First ‘Adipeutic’ Drug Candidate
Executive Summary
Emerging Company Profile: The French biotech is developing a constrained peptide that targets an interaction in body fat tissue in the hopes of treating type 2 diabetes.
You may also be interested in...
Merck Takes A New Shot At Alzheimer’s With Cerevance Deal
The major will use the biotech’s brain cell-focused platform technology to discover new targets for Alzheimer’s disease.
French Medtech System ‘Too Rigorous’ For Innovation To Flourish, Argues Healthtech Expert
David Caumartin is well versed in the both the benefits and drawbacks of being a France-based medtech innovator, having spent almost three decades in the local industry. The VP of France Biotech spoke to Medtech Insight about the new opportunities there to be seized, and the pitfalls to avoid.
GSK Makes ADC Pipeline Comeback With Mersana Deal
The UK major has teamed up with the US biotech to develop the latter’s HER-2 targeted antibody-drug conjugate, a couple of years after the approval of Blenrep, in what is becoming an increasingly competitive space.